Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma

Journal of the Chinese Medical Association

Volumn 73, Issue 3, 2010, Pages 156-160

  Lee, I Cheng ^a   Huang, Yi Hsiang ^a,b   Chu, Chi Jen ^a   Lee, Pui Ching ^a   Lin, Han Chieh ^a   Lee, Shou Dong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

anti HBc positive; chemotherapy; HBV reactivation; non Hodgkin's lymphoma; rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG EFFECT; FEMALE; FOLLICULAR LYMPHOMA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION CONTROL; MULTIPLE CYCLE TREATMENT; SEROLOGY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, FOLLICULAR; VIRUS ACTIVATION;

EID: 77951007337     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(10)70031-9     Document Type: Article

References (26)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
2. Yeo W., and Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43 (2006) 209-220
3. Lok A.S., Liang R.H., Chiu E.K., Wong K.L., Chan T.K., and Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100 (1991) 182-188
4. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
5. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
6. Chang H., Yeh H.C., Su Y.C., and Lee M.H. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab. J Chin Med Assoc 71 (2008) 579-582
7. Han S.M., Teng C.L., Hwang G.Y., Chou G., and Tsai C.A. Primary splenic lymphoma associated with hemophagocytic lymphohis-tiocytosis complicated with splenic rupture. J Chin Med Assoc 71 (2008) 210-213
8. Yeo W., Chan T.C., Leung N.W., Lam W.Y., Mo F.K., Chu M.T., Chan H.L., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27 (2009) 605-611
9. Dervite I., Hober D., and Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344 (2001) 68-69
10. Westhoff T.H., Jochimsen F., Schmittel A., Stoffler-Meilicke M., Schafer J.H., Zidek W., Gerlich W.H., et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102 (2003) 1930
11. Tsutsumi Y., Tanaka J., Kawamura T., Miura T., Kanamori H., Obara S., Asaka M., et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 83 (2004) 58-60
12. Sarrecchia C., Cappelli A., and Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 11 (2005) 189-191
13. Law J.K., Ho J.K., Hoskins P.J., Erb S.R., Steinbrecher U.P., and Yoshida E.M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46 (2005) 1085-1089
14. Niscola P., Del Principe M.I., Maurillo L., Venditti A., Buccisano F., Piccioni D., Amadori S., et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 19 (2005) 1840-1841
15. Sera T., Hiasa Y., Michitaka K., Konishi I., Matsuura K., Tokumoto Y., Matsuura B., et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45 (2006) 721-724
16. Ozgonenel B., Moonka D., and Savasan S. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol 81 (2006) 302
17. Yamagata M., Murohisa T., Tsuchida K., Okamoto Y., Tsunoda S., Nakamura M., Kusano K., et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 48 (2007) 431-433
18. Dillon R., Hirschfield G.M., Allison M.E., and Rege K.P. Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ 337 (2008) a423
19. Wu J.M., Huang Y.H., Lee P.C., Lin H.C., and Lee S.D. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 43 (2009) 496-498
20. Liaw Y.F., Leung N., Kao J.H., Piratvisuth T., Gane E., Han K.H., Guan R., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2 (2008) 263-283
21. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., Hui P., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62 (2000) 299-307
22. Lim S.T., Fei G., Quek R., Lim L.C., Lee L.H., Yap S.P., Loong S., et al. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol 79 (2007) 132-137
23. Aksoy S., Harputluoglu H., Kilickap S., Dede D.S., Dizdar O., Altundag K., and Barista I. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48 (2007) 1307-1312
24. He Y.F., Li Y.H., Wang F.H., Jiang W.Q., Xu R.H., Sun X.F., Xia Z.J., et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 87 (2008) 481-485
25. Marzano A., Angelucci E., Andreone P., Brunetto M., Bruno R., Burra P., Caraceni P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39 (2007) 397-408
26. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 49 (2009) S156-S165